Product information

An Interim Order was issued by the Minister of Health at the request of the Public Health Agency of Canada to allow the authorization for sale of a vaccine for the novel Influenza A H1N1 virus in response to the influenza A H1N1 pandemic. An Interim Order is issued by the Minister of Health under Section 30.1 of the Food and Drugs Act in rare situations where the Minister believes that immediate action is required to deal with a significant risk, direct or indirect, to human health, public safety, or the environment. For more information, please refer to the following link: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/legislation/interimorders-arretesurgence/index-eng.php

Current status:

Cancelled Post Market

Current status date:

2010-09-13

Original market date: ^{See footnote 1}

2009-11-12

Product name:

INFLUENZA A (H1N1) 2009 PANDEMIC MONOVALENT VACCINE (WITHOUT ADJUVANT)

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02337258

Product Monograph/Veterinary Labelling:

Date: 2010-07-22 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

ID BIOMEDICAL CORPORATION OF QUEBEC
2323 Boul Parc Technologique
Quebec
Quebec
Canada G1P 4R8

Class:

Human

Dosage form(s):

Suspension

Route(s) of administration:

Intramuscular

Number of active ingredient(s):

Schedule(s):

Schedule D

American Hospital Formulary Service (AHFS): ^{See footnote 3}

80:12.00

Anatomical Therapeutic Chemical (ATC): ^{See footnote 4}

J07BB02 INFLUENZA, INACTIVATED, SPLIT VIRUS OR SURFACE ANTIGEN

Active ingredient group (AIG) number:^{See footnote5}

0152670001

List of active ingredient(s)
Active ingredient(s)	Strength
HAEMAGGLUTININ FROM A/CALIFORNIA/7/2009 (H1N1)V-LIKE STRAIN (X-179A)	15 MCG / 0.5 ML

New search

Same active ingredient group number

Footnotes

Footnote 1

The earliest marketed date recorded in the Drug Product Database.

Return to footnote 1referrer

Footnote 3

The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. AHFS® Pharmacologic/Therapeutic Classification© used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Information®; ASHP is not responsible for the accuracy of transpositions from the original context.

Return to footnote 3referrer

Footnote 4

The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

Return to footnote 4referrer

Footnote 5

The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

the first portion (2 digits) identifies the number of active ingredients,
the second portion (5 digits) identifies the unique groups of active ingredients(s),
the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of ‑2% to +10%.

Return to footnote 5referrer

Application information

Related information

Contact us

Version 4.0.2

Report a problem or mistake on this page

Report a problem on this page

Date modified:: 2019-03-01